We show that anti‐LRP6 could be of therapeutic benefit to prevent myeloma‐induced bone loss, but superior protection against bone loss and reduced strength was demonstrated when used in combination with anti‐DKK1. Here, LRP6 is linked to plasma cell myeloma.